
    
      Pembrolizumab (200 mg) or placebo will be administered intravenously [IV] on day 1 of each
      3-week cycle. Trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose) will be
      administered IV on day 1 of each 3-week cycle. SOC chemotherapy for the global cohort will
      either be FP (80 mg/m^2 cisplatin administered IV on Day 1 of each 3-week cycle and 800
      mg/m^2 5-fluorouracil [5-FU] administered IV on Days 1-5 of each 3-week cycle) or CAPOX (1000
      mg/m^2 capecitabine administered orally twice daily [BID] on days 1-14 of each 3-week cycle
      and 130 mg/m^2 oxaliplatin administered IV on Day 1 of each 3-week cycle). A Japan cohort
      will receive SOX chemotherapy consisting of S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine
      [CDHP], and potassium oxonate [Oxo]) administered orally BID according to Body Surface Area
      (BSA) on Days 1-14 of each 3-week cycle and oxaliplatin (130 mg/m^2) administered IV on Day 1
      each 3-week cycle.
    
  